NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT03081923 2021-05-14APACHEFondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2 Terminated36 enrolled